Form 6-K ASTRAZENECA PLC For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
AstraZeneca (AZN) Tops Q2 EPS by 21c; Boosts Outlook
July 31, 2014 8:53 AM EDTAstraZeneca (NYSE: AZN) reported Q2 EPS of $1.30, $0.21 better than the analyst estimate of $1.09. Revenue for the quarter came in at $6.45 billion versus the consensus estimate of $6.24 billion.
The Company increases its revenue and Core EPS guidance for the full year:
Revenue is expected to be in line with 2013 at CER, an increase on our previous guidance of low-to-mid single digit percentage decline. Core EPS... More


